Cellectar Biosciences Inc. stocks have been trading up by 39.2 percent following highly positive clinical trial advancement news
Click Here for a Millionaire's POV on Trading CLRB
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Cellectar Biosciences enrolled the first patient in a Phase 1b trial of CLR 125 for relapsed or refractory triple negative breast cancer.
- The Phase 1b study will track tumor uptake, safety, and early signs of efficacy to lock in a Phase 2 dose.
- The CLR 125 program extends Cellectar’s PDC radioconjugate platform beyond its lead drug iopofosine I‑131, giving CLRB a broader pipeline story.
Live Update At 10:03:28 EDT: On Tuesday, May 05, 2026 Cellectar Biosciences Inc. stock [NASDAQ: CLRB] is trending up by 39.2%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CLRB has been trading like a classic low-float biotech reacting to a fresh catalyst. Over the past few weeks, Cellectar Biosciences stock climbed from the mid‑$2s to a recent close around $3.93, with a spike as high as $4.70 on the most recent trading day. That’s a big percentage move in a short window, and traders are clearly crowding into CLRB around the new trial news.
The intraday tape tells the same story. Pre‑market, CLRB ripped from roughly $3.13 to a peak near $7.20 before fading and settling under $4 by 10:00. That huge range shows how aggressive momentum trading has become in this name. For day traders, this is a playground — but also a risk trap if you chase late.
More Breaking News
- RXT Stock Climbs As Rackspace Technology Reshapes Cloud Leadership
- Celcuity CELC Soars On Strong Phase 3 Cancer Data
- Ford Stock Under Pressure As Costs Climb And Recalls Hit
- RNTX Stock Dips As Traders Weigh Deep Losses And Cash Runway
Fundamentally, Cellectar Biosciences is still a development‑stage biotech. The latest report shows net income of about -$5.3M for the quarter and heavy research and development spending. On the positive side, CLRB holds roughly $13.2M in cash and minimal debt, with a current ratio near 3, giving the company breathing room to run trials. For traders, the combination of solid cash, a small market cap, and binary clinical catalysts is exactly what fuels sharp CLRB swings.
Why Traders Are Watching CLRB Now
CLRB is back on radar because of one clear catalyst: Cellectar Biosciences has dosed the first patient in its Phase 1b trial of CLR 125 for relapsed or refractory triple negative breast cancer. First‑patient enrollment is more than a press release milestone. It marks the point where a concept moves into real human data, and traders know that’s when biotech stories start to matter.
Triple negative breast cancer is one of the tougher cancers to treat. When a small‑cap like CLRB targets a high‑need area with a differentiated technology — in this case an Auger‑emitting radioconjugate — the market tends to pay attention. The Phase 1b trial will measure how much CLR 125 actually hits tumors, how safe it is, and whether there are early hints it helps patients. Those readouts won’t show up overnight, but every step forward sets up the next possible trading catalyst.
For Cellectar Biosciences, this trial also changes the narrative. Until now, most of the story centered on its lead asset, iopofosine I‑131. With CLR 125 moving into the clinic, CLRB is showing traders that its phospholipid drug conjugate platform is more than a one‑drug bet. That diversification can matter. It reduces the sense that everything rides on a single binary event and gives CLRB multiple shots on goal.
The chart is responding to that story. We’re seeing big gaps, heavy volume, and wide intraday ranges — all the hallmarks of a momentum setup. Short‑term traders are focusing on support in the low‑$3s and resistance near the recent pre‑market highs, while swing traders are watching how CLRB holds above prior consolidation in the high‑$2s.
Conclusion
Right now CLRB sits at the intersection of science and speculation. Cellectar Biosciences has the cash to keep pushing trials, a relatively clean balance sheet, and a fresh clinical catalyst with CLR 125 in triple negative breast cancer. At the same time, the financials are exactly what you expect from a development‑stage biotech — no real revenue yet, negative earnings, and a deep reliance on capital markets and data milestones.
For traders, that mix can be powerful. CLRB’s expanding PDC radioconjugate platform, with iopofosine I‑131 and now CLR 125, creates multiple upcoming data points that can move the stock fast in either direction. The recent pre‑market spike from the $3s to above $7 and the fade back under $4 underline how ruthless that volatility can be. Cellectar Biosciences will reward disciplined trading, not hope.
The key is to treat CLRB like a trading vehicle, not a lottery ticket. Plan entries around clear levels, respect liquidity, and size positions assuming gaps can be huge both ways. As Tim Sykes loves to repeat, “Cut losses quickly — that’s how you stay in the game long enough to catch the big winners.” That goes hand in hand with the idea that you need conviction and clarity before you click the buy button; as Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.”. CLRB fits that mindset perfectly: high potential, high risk, and best approached with a strict trading plan and zero emotion.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.